The pathway-selective estrogen receptor ligand WAY-169916 displays differential activity in ischemia-reperfusion injury models.

@article{Harnish2006ThePE,
  title={The pathway-selective estrogen receptor ligand WAY-169916 displays differential activity in ischemia-reperfusion injury models.},
  author={Douglas C. Harnish and Xiaorong Liu and Thomas Kenney and Richard C. Winneker and Chris Chadwick and Gregory S. Friedrichs and Edward J. Kilbourne},
  journal={Journal of cardiovascular pharmacology},
  year={2006},
  volume={47 6},
  pages={
          788-95
        }
}
We previously reported on the development of a pathway-selective estrogen receptor (ER) ligand, WAY-169916, that has ER-dependent antiinflammatory activity and is devoid of classic ER transcriptional activity. In the current study, WAY-169916 and 17beta-estradiol (17beta-E2) were evaluated for protective activity in models of cardiac ischemia-reperfusion injury. In rats subjected to cardiac ischemia-reperfusion injury by occlusion of the left coronary artery, infarct size relative to the area… CONTINUE READING
BETA